Francois Brisebois
Stock Analyst at Oppenheimer
(1.68)
# 2,555
Out of 5,182 analysts
75
Total ratings
36%
Success rate
-1.37%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics | Maintains: Outperform | $21 → $23 | $12.96 | +77.47% | 3 | Apr 6, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $95 → $105 | $60.93 | +72.33% | 8 | Feb 25, 2026 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $4.10 | +95.12% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $5.16 | +16.28% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $31.54 | +153.65% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.34 | +199.63% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $2.69 | +48.70% | 1 | Jan 29, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $31.05 | +96.46% | 6 | Jan 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $330.99 | -50.75% | 4 | Oct 31, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $18.04 | +204.88% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.12 | +12,462.81% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $6.32 | -5.06% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.96 | +177.78% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $39.51 | -64.57% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $14.61 | +344.90% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.58 | +532.91% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $16.57 | +117.26% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $2,500 → $1,500 | $2.99 | +50,151.26% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.23 | +438,924.39% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $2.00 | +450.00% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $2.04 | +782.35% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $8.89 | +462.43% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.62 | +519,213.99% | 1 | Feb 4, 2020 |
Entrada Therapeutics
Apr 6, 2026
Maintains: Outperform
Price Target: $21 → $23
Current: $12.96
Upside: +77.47%
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $95 → $105
Current: $60.93
Upside: +72.33%
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $4.10
Upside: +95.12%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $5.16
Upside: +16.28%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $31.54
Upside: +153.65%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.34
Upside: +199.63%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $2.69
Upside: +48.70%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $31.05
Upside: +96.46%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $330.99
Upside: -50.75%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $18.04
Upside: +204.88%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.12
Upside: +12,462.81%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $6.32
Upside: -5.06%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.96
Upside: +177.78%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $39.51
Upside: -64.57%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $14.61
Upside: +344.90%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.58
Upside: +532.91%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $16.57
Upside: +117.26%
Apr 3, 2023
Maintains: Outperform
Price Target: $2,500 → $1,500
Current: $2.99
Upside: +50,151.26%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.23
Upside: +438,924.39%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $2.00
Upside: +450.00%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $2.04
Upside: +782.35%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $8.89
Upside: +462.43%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.62
Upside: +519,213.99%